Adimab

Adimab describes itself as an antibody discovery and engineering platform company that partners with biopharma leaders to advance protein-based therapeutics. Founded in 2007, it states that its proprietary yeast-based platform combines fully human synthetic and immune libraries to deliver IgGs, HCAbs, multispecifics, TCRs and other therapeutic proteins. The company reports 140+ biopharma partnerships, 675+ therapeutic programs initiated, 90+ clinical programs initiated and 6 commercial products, and states that it has no internal pipeline, focusing its resources on partners' programs.

Adimab states it was founded in 2007 and has become the biopharma industry's partner of choice for therapeutic antibody discovery and engineering. The company says it set out to bring full-length IgG discovery into a controllable eukaryotic system, combining in vitro speed with eukaryotic quality. For more than 15 years, it states, its platform and collaborative model have fueled partnerships, with dozens of programs progressing from discovery into clinical development. Adimab describes its platform as a highly engineered yeast strain and a highly controllable in vitro eukaryotic system that allows discovery and engineering in the final IgG and HCAb format.

The biopharma industry's partner of choice for therapeutic antibody discovery and engineering, with no internal pipeline.

• Antibody discovery

  Access to high-quality synthetic and immune libraries delivering therapeutic antibodies for the clinic.

• Antibody engineering

  Transforming leads into high-affinity, developable candidates through guided engineering and real-time screening.

• Multispecific antibodies and T cell engagers

  Engineering multispecifics, including T-cell engagers, of diverse formats for function, manufacturability, and scalability.

• Protein and TCR engineering

  AI-guided engineering of non-antibody proteins for tailored binding, stability, and expression.

1. 1Antibody Discovery And Engineering Platform | Adimabadimab.com
2. 2Who We Are | Adimabadimab.com
3. 3Partnering to Advance Biologics | Adimabadimab.com